AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Pulmonary Arterial Hypertension

Recent research efforts aimed at curing Pulmonary Arterial Hypertension.

Last updated

Pulmonary Arterial Hypertension

Overview

Pulmonary arterial hypertension (PAH) is a rare form of high blood pressure in the arteries of the lungs. The small lung arteries become narrowed and structurally damaged—a process called vascular remodeling—so the right side of the heart must work progressively harder and can ultimately fail. PAH can be idiopathic (without an identified cause), inherited, or associated with conditions such as connective-tissue disease, congenital heart disease, HIV, portal hypertension, or certain drugs. It affects women more often than men and remains life-threatening despite major advances. In a contemporary United States registry, mortality was about 8% at one year and 21% at three years, with much worse outcomes in people classified as high risk. Contemporary PAH mortality registry (pmc.ncbi.nlm.nih.gov)

Current care is aimed at lowering pulmonary vascular resistance, protecting the right ventricle, and reaching a low-risk clinical status rather than eliminating the underlying disease. Treatment commonly combines medicines acting on the endothelin, nitric-oxide, and prostacyclin pathways; severe disease may require continuous intravenous or subcutaneous prostacyclin treatment and referral for lung transplantation. 2022 ESC/ERS PAH guideline Sotatercept, approved in the United States on March 26, 2024, added the first approved therapy designed to counter abnormal growth-factor signaling involved in vascular remodeling. FDA Winrevair snapshot (publications.ersnet.org)

Scope of Recent Research (2020–present)

Research since 2020 has been notably active and has shifted from treating vessel constriction alone toward reversing vascular remodeling, restoring dysfunctional BMPR2/BMP signaling, repairing the lung endothelium, and preventing right-heart failure. The strongest clinical advance is activin-signaling inhibition with sotatercept, while mRNA replacement, engineered-cell therapy, inhaled anti-proliferative drugs, and RNA-based approaches remain early-stage. No therapy has yet been shown to permanently cure PAH or reliably reverse disease after treatment is withdrawn, but the field now has credible disease-modifying strategies rather than vasodilation alone. Sotatercept phase 3 trial BMPR2 mRNA nanoparticle study (nejm.org)

Major Breakthroughs and Emerging Therapies

The clearest breakthrough has been sotatercept, a fusion protein that traps activin-family ligands and is intended to rebalance signaling within the transforming growth factor-beta (TGF-β) superfamily. This matters because reduced bone morphogenetic protein receptor type 2 (BMPR2) signaling and excessive activin-related signaling can drive abnormal growth and remodeling in pulmonary vessels. In the phase 3 STELLAR trial, adding sotatercept to established PAH therapy improved walking distance, pulmonary vascular resistance, functional class, and biomarkers over 24 weeks; it also reduced clinical-worsening events. STELLAR phase 3 trial (nejm.org) Although it is not a cure, sotatercept is important because it is the first approved treatment with compelling evidence of modifying disease biology beyond the three traditional vasodilator pathways.

A complementary anti-remodeling approach is inhaled seralutinib, a tyrosine-kinase inhibitor designed to inhibit PDGFR, CSF1R, and c-KIT—signaling proteins implicated in cell proliferation, inflammation, and fibrosis in PAH. Delivering it by dry-powder inhaler aims to concentrate treatment in the lung while limiting body-wide exposure. In the phase 2 TORREY trial, seralutinib produced a statistically significant placebo-adjusted reduction in pulmonary vascular resistance at 24 weeks in patients already receiving background PAH therapy. TORREY phase 2 trial (pubmed.ncbi.nlm.nih.gov)

Cell and regenerative therapies seek to restore a healthier pulmonary vascular lining. In the SAPPHIRE study, researchers infused patients’ own endothelial progenitor cells after engineering them to express endothelial nitric-oxide synthase (eNOS), an enzyme that supports blood-vessel function. The trial was stopped early during the COVID-19 pandemic after enrolling only 12 of a planned 45 participants, so it cannot establish efficacy; however, four monthly infusions were tolerated and the small dataset suggested a possible exercise-capacity benefit. SAPPHIRE eNOS-cell trial Another early phase study of allogeneic cardiosphere-derived cells found no short-term treatment-related safety signal, but no meaningful average improvement in pulmonary pressures or vascular resistance. ALPHA cell-therapy study (pubmed.ncbi.nlm.nih.gov)

Gene- and RNA-replacement strategies are particularly relevant to heritable PAH, in which BMPR2 is the most important known genetic contributor. In 2025, investigators reported lung-endothelium-targeted lipid nanoparticles carrying BMPR2 messenger RNA (mRNA). In two rat models with established pulmonary hypertension, repeated treatment restored BMPR2-related signaling, reduced vascular obstruction and right-ventricular remodeling, and improved measures of right-heart function. BMPR2 mRNA nanoparticle study This is an encouraging proof of concept for protein replacement, not gene editing: the mRNA is temporary, the work was performed in animals, and human safety, targeting, dose durability, and immune effects remain unknown. (pmc.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

Sotatercept has generated the most consequential recent clinical data. Merck-sponsored STELLAR was a phase 3 trial in 323 adults with symptomatic PAH receiving background treatment; its results supported U.S. approval. STELLAR phase 3 trial FDA Winrevair snapshot In the subsequent phase 3 ZENITH trial of 172 adults at high risk of death despite maximum tolerated therapy, the composite outcome of death, lung transplantation, or hospitalization for worsening PAH occurred in 17.4% of patients receiving sotatercept versus 54.7% receiving placebo; the study was stopped early after a prespecified interim efficacy analysis. ZENITH phase 3 trial (nejm.org)

The phase 3 HYPERION trial tested sotatercept earlier, within the first year after PAH diagnosis. Published results reported deterioration in exercise performance related to PAH in 5.0% of sotatercept-treated participants versus 28.8% of placebo-treated participants, while longer-term follow-up remains important for determining whether earlier use changes survival, transplant need, or the possibility of sustained remission. HYPERION trial Seralutinib has progressed from its positive phase 2 TORREY study into the phase 3 PROSERA program, sponsored by Gossamer Bio; its key test will be whether pulmonary vascular improvements translate into fewer clinical events and acceptable long-term tolerability. Seralutinib open-label extension (nejm.org)

Methodologies and Scientific Approaches

Researchers combine patient-derived blood and tissue measurements with right-heart catheterization, echocardiography, exercise testing, functional class, pulmonary vascular resistance, and NT-proBNP—a blood marker of heart strain—to assess whether a treatment improves both symptoms and the underlying circulation. Modern trials increasingly emphasize time to clinical worsening, hospitalization, transplantation, or death rather than walking distance alone. ZENITH phase 3 trial 2022 ESC/ERS PAH guideline (nejm.org)

For potential cures, laboratories use human pulmonary artery endothelial and smooth-muscle cells, patient genetic data, induced pluripotent stem-cell models, and animal models such as monocrotaline and SU5416-hypoxia rats. These platforms are used to test whether candidate therapies can reverse vessel-muscle thickening, restore endothelial survival, normalize BMPR2-SMAD signaling, and improve right-ventricular structure and function. Targeted lipid nanoparticles are one delivery platform; their purpose is to deliver mRNA preferentially to pulmonary endothelial cells rather than broadly throughout the body. BMPR2 mRNA nanoparticle study NHLBI pulmonary-hypertension research (pmc.ncbi.nlm.nih.gov)

Leading Institutions and Funding

The clinical-translational effort is international. Major recent sotatercept trials involved centers including Université Paris-Saclay/Hôpital Bicêtre, University of Michigan, University of Colorado, Harvard-affiliated Brigham and Women’s Hospital, Imperial College London, Hannover Medical School, and the Universities of Giessen and Marburg; Merck funded the pivotal STELLAR and ZENITH programs. STELLAR phase 3 trial ZENITH phase 3 trial Gossamer Bio is advancing seralutinib, while the Ottawa Hospital Research Institute and collaborating Canadian centers led the SAPPHIRE engineered-cell study. TORREY phase 2 trial SAPPHIRE eNOS-cell trial (nejm.org)

Public and nonprofit infrastructure remains essential for high-risk, early-stage research. The U.S. National Heart, Lung, and Blood Institute (NHLBI) supports PAH resources including the PAH Biobank, the Pulmonary Hypertension Breakthrough Initiative, PVDOMICS phenotyping, and translational-development programs. NHLBI pulmonary-hypertension research One active NHLBI-supported Stanford project on BMPR2, monocytes, and macrophages in pulmonary arterial hypertension listed fiscal-year 2026 support of $611,035. NIH RePORTER BMPR2 project The Pulmonary Hypertension Association also offers targeted awards of up to $50,000 per year, including initiatives with the American Heart Association. PHA research grants (nhlbi.nih.gov)

Strengths, Limitations, and Challenges

The field’s principal strength is that it has finally produced therapies that appear to affect vascular remodeling as well as vasodilation. Sotatercept’s results across lower-risk, newly diagnosed, and high-risk populations are unusually consistent for PAH, and its effect on hard clinical outcomes in ZENITH is especially meaningful. STELLAR phase 3 trial ZENITH phase 3 trial Yet improvement is not proof of cure: patients remained on background medicines, and it is unknown whether disease will recur if sotatercept is stopped. Sotatercept also requires monitoring for increased hemoglobin, low platelet counts, bleeding, and small visible blood-vessel changes called telangiectasias. FDA Winrevair snapshot (nejm.org)

Gene, RNA, and cell therapies confront more fundamental translational barriers. PAH is biologically diverse: even among people with a BMPR2 variant, not all develop disease, indicating that additional genetic, hormonal, immune, metabolic, or environmental factors matter. Heritable PAH overview Animal models do not fully reproduce the complex vascular lesions and right-heart disease seen in humans, while targeted delivery must be durable enough to work but controlled enough to avoid inflammation, unintended distribution, or excessive vessel growth. Cell therapies also face manufacturing, cost, consistency, and scalability challenges. BMPR2 mRNA nanoparticle study SAPPHIRE eNOS-cell trial (ncbi.nlm.nih.gov)

Outlook and Future Directions

As of October 27, 2026, a true cure for PAH is not close enough to promise, but the trajectory is more encouraging than it was in 2020. The next milestones are durable outcome data for earlier sotatercept use; phase 3 evidence for inhaled anti-remodeling drugs such as seralutinib; and successful translation of endothelial-targeted BMPR2 restoration or regenerative-cell approaches from animal models into carefully monitored first-in-human studies. A realistic curative strategy may ultimately require personalized combination treatment that corrects a patient’s dominant disease mechanism, reverses established vascular lesions, and preserves right-ventricular recovery after conventional drugs can be reduced or withdrawn. HYPERION trial BMPR2 mRNA nanoparticle study (nejm.org)

References

Don't see your disease? Request a report